Alcatel-Lucent (NYSE: ALU) is down nearly 6% premarket to $5.89, relative to a 52-week range of $2.25-$6.63. The company recently issued its outlook for 2011.

ARM Holdings PLC (NASDAQ: ARMH) is up 3% premarket on moderate volume to $28.47, relative to a 52-week range of $9.50-$32.18.

Limelight Networks (NASDAQ: LLNW) is up 5% premarket to $6.70, relative to a 52-week range of $6.26-$6.59. The company released earnings showed a loss below street expectations, but 2Q guidance above expectations.

Obagi Medical Products, Inc. (NASDAQ: OMPI) is up 26% premarket to $9.51, relative to a 52-week range of $9.58-$14.20. The company issued Q2 guidance well below expectations.

GlaxoSmithKline (NYSE: GSK) reorganized its corporate structure, increasing focus on emerging markets such as China, Russia, Brazil, India and the Middle East. New CEO Andrew Witty, who will take over on May 22, approves the moves. Shares are down $0.25 to $44.64 in mid-day trading. The 52-week range is $40.51 to $58.23.

Merck (NYSE: MRK) down slightly despite news Monday that they are to cut 1,200 sales jobs to cut costs. Yesterday, shares dropped $0.47. Shares are down $0.13 to $38.85 in mid-day trading on thin volume. The 52-week range is $36.80 to $61.62.

Obagi Medical Products, Inc. (NASDAQ: OMPI) dropping over 20% today after earnings reported Monday missed Street estimates. The skin care products maker showed a profit of $3 million for EPS of $0.13. Thomson analysts estimated $0.18 EPS. The company also reduced its yearly outlook. Shares are down $1.81 to $6.98, grazing new lows. The 52-week range is $6.80 to $25.60.

StemCells Inc. (NASDAQ: STEM) sinking after first quarter earnings were reported this morning. They showed a net loss of $6.5 million or -$0.08 EPS, wider that -$0.06 EPS in 2007. Shares are down over 5% to $1.58. The 52-week range is $1.00 to $2.69.

Teva Pharmaceuticals (NASDAQ: TEVA) reported solid first quarter earnings that beat estimates. Excluding a large charge for the $382 million acquisition of CoGenesys, Teva showed a net income of $529 million or $0.64 EPS, beating estimates of $0.63 EPS. Shares are down marginally to $46.49. The 52-week range is $38.13 to $50.00.

Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) shares are dropping today after rising almost 40% yesterday after reporting narrower first quarter losses last Thursday, beating expectations. Also yesterday, Caris initiated coverage on the company with a “Buy” rating and a $22.00 price target, specifically citing the expectation that schizophrenia treatment Fanapta, will gain regulatory approval in July. Today, shares are down over 6% to $5.10 on unusually high trading volume. The 52-week range is $2.70 to $22.49.

Rachel Lopez
May 6, 2008

Anika Therapeutics Inc. (NASDAQ: ANIK) moving up after reporting solid first quarter earnings this morning. The leader in tissue protection products and healing and repair based on hyaluronic acid (“HA”) technology showed double digit revenues in each product line for total revenue growth of 39%. Shares are up over 12% at $9.68. The 52-week range is $7.85 to $22.49.

Athersys, Inc. (NASDAQ: ATHX) dropping a whopping 23% today on no relevant news. Shares are down $0.70 to $2.30. The 52-week range is $1.55 to $10.00.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) up over 8% to $5.37. They announced that first quarter earnings will be released May 8 after market close and on May 9 they will provide a pipeline update. The 52-week range is $4.19 to $11.00.

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that under its collaboration agreement with Merck (NYSE: MRK), they achieved a preclinical milestone with a novel Toll-Like Receptor 9 agonists for an adjuvant in cancer vaccines. Idera should receive a milestone payment from Merck. Idera is up 3% to $14.34 off a 52-week range of $6.21 to $14.00. Merck is up over 1% to $38.77 on a 52-week range of $ 36.80 to $61.62. 

Obagi Medical Products, Inc. (NASDAQ: OMPI) is up over 7% to $8.62 on now news. The 52-week range for the skincare developer is $6.80 to $25.60.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) up 5% today after first quarter results were released this morning. They showed a loss of $11.6 million, or $0.15 EPS, narrower than the $29.9 million loss in first quarter 2007. Shares are up $1.11 to $20.73. The 52-week range is $13.55 to $28.74.

SCOLR Pharma Inc. (AMEX: DDD) up over 8% today after announcing that it entered into a lease buyout deal to move into a cheaper location, with the proceeds of over $4 million, the company said it will be able to fund 2009 expenses. Shares are trading at $1.26. The 52-week range is $0.13 to $4.07.

Sequenom Inc. (NASDAQ: SQNM) up today after reporting financial results after close yesterday. They posted a net loss of $8.6 million compared to a loss of $3.8 million in first quarter last year. Revenues increased by 7%. Shares are trading up over 8% to $6.85 on a 52-week range of $3.16 to $11.63.

Rachel Lopez
May 1, 2008

• DuPont (NYSE: DD) started as Outperform at Credit Suisse.
• Elan (NYSE: ELN) started as Outperform at Credit Suisse.
• Logitec (NASDAQ: LOGI) started as Buy at Citigroup.
• Microsoft (NASDAQ: MSFT) started as Buy at Jefferies.
• Obagi Medical (NASDAQ: OMPI) raised to Outperform at Oppenheimer.
• PDL BioPharma (NASDAQ: PDLI) cut to Equal-Weight at Lehman Brothers.
• Red Robin Gourmet Burgers (NASDAQ: RRGB) raised to Overweight at JP Morgan.
• RiskMetrics Group (NYSE: RMG) started as Outperform at Credit Suisse; started as Neutral at Banc of America.
• Whirlpool (NYSE: WHR) downgraded to Underweight at JPMorgan.
• Xinhua Financial Media (NASDAQ: XFML) downgraded to Neutral at JP Morgan.

Jon C. Ogg
March 5, 2008